DrugPatentWatch Database Preview
Teva Company Profile
» See Plans and Pricing
What is the competitive landscape for TEVA, and when can generic versions of TEVA drugs launch?
TEVA has seven hundred and one approved drugs.
There are seventy-three US patents protecting TEVA drugs. There are forty-three tentative approvals on TEVA drugs.
There are eight hundred and sixteen patent family members on TEVA drugs in forty-six countries and seven hundred and eighty-eight supplementary protection certificates in eighteen countries.
Summary for Teva
International Patents: | 816 |
US Patents: | 73 |
Tradenames: | 479 |
Ingredients: | 418 |
NDAs: | 701 |
Patent Litigation for Teva: | See patent lawsuits for Teva |
PTAB Cases with Teva as petitioner: | See PTAB cases with Teva as petitioner |
Drugs and US Patents for Teva
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharm | AUSTEDO | deutetrabenazine | TABLET;ORAL | 208082-001 | Apr 3, 2017 | RX | Yes | No | 9,296,739 | Start Trial | Y | Start Trial | |||
Teva Pharm | ARMONAIR DIGIHALER | fluticasone propionate | POWDER;INHALATION | 208798-004 | Feb 20, 2020 | RX | Yes | No | 8,651,103 | Start Trial | Y | Start Trial | |||
Teva | AZILECT | rasagiline mesylate | TABLET;ORAL | 021641-001 | May 16, 2006 | AB | RX | Yes | No | 7,815,942 | Start Trial | Y | Y | Start Trial | |
Teva | FAMOTIDINE | famotidine | TABLET;ORAL | 075311-001 | Apr 16, 2001 | DISCN | No | No | Start Trial | Start Trial | |||||
Teva | ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE | metformin hydrochloride; rosiglitazone maleate | TABLET;ORAL | 077337-005 | May 19, 2017 | DISCN | No | No | Start Trial | Start Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Teva
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Branded Pharm | NASAREL | flunisolide | SPRAY, METERED;NASAL | 020409-001 | Mar 8, 1995 | 4,782,047 | Start Trial |
Teva Pharms Usa | COPAXONE | glatiramer acetate | INJECTABLE;SUBCUTANEOUS | 020622-003 | Jan 28, 2014 | 6,342,476 | Start Trial |
Teva Branded Pharm | QVAR 80 | beclomethasone dipropionate | AEROSOL, METERED;INHALATION | 020911-001 | Sep 15, 2000 | 5,605,674 | Start Trial |
Teva Womens | PREFEST | estradiol; norgestimate | TABLET;ORAL | 021040-001 | Oct 22, 1999 | 5,108,995 | Start Trial |
Teva Pharm | ARMONAIR RESPICLICK | fluticasone propionate | POWDER;INHALATION | 208798-001 | Jan 27, 2017 | 6,446,627 | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for TEVA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-02-26 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
➤ Subscribe | Tablets | 1 mg/0.02 mg and 75 mg | ➤ Subscribe | 2006-04-17 |
➤ Subscribe | Tablets | 0.15 mg/0.02 mg, 0.15 mg/0.025 mg, 0.15 mg/0.03 mg and 0.01 mg | ➤ Subscribe | 2013-07-10 |
➤ Subscribe | Tablets | 0.15 mg/0.03 mg/0.01 mg | ➤ Subscribe | 2008-01-22 |
➤ Subscribe | for Injection | 3.5 mg/vial | ➤ Subscribe | 2016-10-26 |
➤ Subscribe | Injection | 40 mg/mL, 1 mL pre-filled syringe | ➤ Subscribe | 2014-01-29 |
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | Tablets | 5 mg, 10 mg, 20 mg, 30 mg | ➤ Subscribe | 2009-11-18 |
➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-05-17 |
➤ Subscribe | Tablets | 0.1 mg/0.02 mg and 0.01 mg | ➤ Subscribe | 2009-11-16 |
➤ Subscribe | Tablets | 0.15 mg/0.03 mg | ➤ Subscribe | 2004-03-29 |
➤ Subscribe | Extended-release Capsule | 15 mg and 30 mg | ➤ Subscribe | 2008-08-11 |
➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
Premature patent expirations for TEVA
Expiration due to failure to pay maintenance fee
Patent Number | Expiration Date |
---|---|
Start Trial | Start Trial |
International Patents for Teva Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 209755 | Start Trial |
Austria | 518561 | Start Trial |
World Intellectual Property Organization (WIPO) | 2012048867 | Start Trial |
Slovenia | 1294421 | Start Trial |
Portugal | 2073795 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Teva Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3143995 | 2019C/528 | Belgium | Start Trial | PRODUCT NAME: EVEROLIMUS OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; AUTHORISATION NUMBER AND DATE: EU/1/09/538/001, 003, 004, 006-010 (C(2016)3286) 20160530 |
0678503 | C300499 | Netherlands | Start Trial | PRODUCT NAME: COMBINATIE OMVATTEND ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110114 |
0497512 | 9891028-4 | Sweden | Start Trial | PRODUCT NAME: RIZATRIPTAN, N.N-DIMETYL-2-(5-(1, 2, 4-TRIAZOL-1-YLMETYL)-1H-INDOL-3-YL)ET)-1H-I, EVENTUELLT I FORM AV ETT FARMACEUTISKT GODTAGBART SALT, SPECIELLT DA RIZATRIPTANBENSOAT |
1663240 | 59/2015 | Austria | Start Trial | PRODUCT NAME: KOMBINATION VON RILPIVIRIN ODER EINEM PHARMAZEUTISCH ANNEHMBAREN SALZ VON RILPIVIRIN, EINSCHLIESSLICH DES HYDROCHLORIDSALZES VON RILPIVIRIN, TENOFOVIR, INSBESONDERE TENOFOVIRDISOPROXILFUMARAT, UND EMTRICITABIN; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128 |
0961612 | 300417 | Netherlands | Start Trial | PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE: EU/1/07/428/001 20080114 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.